Age-standardised rate of mortality from oral cancer (ICD-10 codes C00-C14) in persons of all ages and sexes per 100,000 population.RationaleOver the last decade in the UK (between 2003-2005 and 2012-2014), oral cancer mortality rates have increased by 20% for males and 19% for females1Five year survival rates are 56%. Most oral cancers are triggered by tobacco and alcohol, which together account for 75% of cases2. Cigarette smoking is associated with an increased risk of the more common forms of oral cancer. The risk among cigarette smokers is estimated to be 10 times that for non-smokers. More intense use of tobacco increases the risk, while ceasing to smoke for 10 years or more reduces it to almost the same as that of non-smokers3. Oral cancer mortality rates can be used in conjunction with registration data to inform service planning as well as comparing survival rates across areas of England to assess the impact of public health prevention policies such as smoking cessation.References:(1) Cancer Research Campaign. Cancer Statistics: Oral – UK. London: CRC, 2000.(2) Blot WJ, McLaughlin JK, Winn DM et al. Smoking and drinking in relation to oral and pharyngeal cancer. Cancer Res 1988; 48: 3282-7. (3) La Vecchia C, Tavani A, Franceschi S et al. Epidemiology and prevention of oral cancer. Oral Oncology 1997; 33: 302-12.Definition of numeratorAll cancer mortality for lip, oral cavity and pharynx (ICD-10 C00-C14) in the respective calendar years aggregated into quinary age bands (0-4, 5-9,…, 85-89, 90+). This does not include secondary cancers or recurrences. Data are reported according to the calendar year in which the cancer was diagnosed.Counts of deaths for years up to and including 2019 have been adjusted where needed to take account of the MUSE ICD-10 coding change introduced in 2020. Detailed guidance on the MUSE implementation is available at: https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/articles/causeofdeathcodinginmortalitystatisticssoftwarechanges/january2020Counts of deaths for years up to and including 2013 have been double adjusted by applying comparability ratios from both the IRIS coding change and the MUSE coding change where needed to take account of both the MUSE ICD-10 coding change and the IRIS ICD-10 coding change introduced in 2014. The detailed guidance on the IRIS implementation is available at: https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/bulletins/impactoftheimplementationofirissoftwareforicd10causeofdeathcodingonmortalitystatisticsenglandandwales/2014-08-08Counts of deaths for years up to and including 2010 have been triple adjusted by applying comparability ratios from the 2011 coding change, the IRIS coding change and the MUSE coding change where needed to take account of the MUSE ICD-10 coding change, the IRIS ICD-10 coding change and the ICD-10 coding change introduced in 2011. The detailed guidance on the 2011 implementation is available at https://webarchive.nationalarchives.gov.uk/ukgwa/20160108084125/http://www.ons.gov.uk/ons/guide-method/classifications/international-standard-classifications/icd-10-for-mortality/comparability-ratios/index.htmlDefinition of denominatorPopulation-years (aggregated populations for the three years) for people of all ages, aggregated into quinary age bands (0-4, 5-9, …, 85-89, 90+)

This statistic shows the rate of mortality to larynx cancer incidence in England in 2016, by region and gender. The larynx is located in the neck and is a part of the respiratory tract, it connects the pharynx and the trachea. Cancer of the larynx occurs when cells within the larynx begin to grow abnormally. In the east of England in this year, ** percent of males and ** of females who were diagnosed died as a result of cancer of the larynx.

BackgroundHead and neck cancer (HNC) is one of the most prevalent malignant tumors, with higher incidence and mortality rates in men than in women, particularly for lip and oral cavity, nasopharyngeal, laryngeal, and other pharyngeal cancers. This study investigates global trends in the occurrence of these cancers in men from 1990 to 2021 and analyzes their changing trends to guide healthcare policymakers in resource allocation.MethodsUsing data from the 2021 Global Burden of Disease Study (GBD 2021), this study assesses the global prevalence, incidence, mortality, and disability-adjusted life years (DALYs) for male head and neck cancers. It also evaluates the relationship between cancer burden and economic development using the Socio-Demographic Index (SDI) and analyzes the risk factors for male head and neck cancer mortality and DALYs.ResultsFrom 1990 to 2021, the impact of male head and neck cancers increased at varying rates. In 2021, there were 968,573 prevalent cases of lip and oral cavity cancer, 272,917 incident cases, 136,890 deaths, and 3,969,812 DALYs globally. The burden of nasopharyngeal, laryngeal, and other pharyngeal cancers was lower, with 385,913, 939,924, and 258,723 prevalent cases, respectively. The age-standardized incidence rates for all four cancers were positively correlated with the SDI. Key risk factors for male head and neck cancers include smoking and alcohol consumption. Additional risk factors include chewing tobacco for lip and oral cavity cancer deaths, formaldehyde exposure for nasopharyngeal cancer, and occupational exposure to sulfuric acid and asbestos for laryngeal cancer.ConclusionsLip and oral cavity cancer remains the most burdensome, while nasopharyngeal cancer is increasing in East and Southeast Asia. Laryngeal cancer has declined in high-SDI regions, while other pharyngeal cancers are rising. Gender and lifestyle are key risk factors, underscoring the need for early prevention, particularly in resource-limited areas. As the global population ages, targeted prevention and improved healthcare infrastructure are essential.

Abstract

HANCOCK is a comprehensive, monocentric dataset of 763 head and neck cancer patients, including diverse data modalities. It contains histopathology imaging (whole-slide images of H&E-stained primary tumors and tissue microarrays with immunohistochemical staining) alongside structured clinical data (demographics, tumor pathology characteristics, laboratory blood measurements) and textual data (de-identified surgery reports and medical histories). All patients were treated curatively, and data span diagnoses from 2005–2019. This multimodal collection enables research into integrative analyses – for example, combining histologic features with clinical parameters for outcome prediction. Early analyses have demonstrated that fusing these modalities improves prognostic modeling compared to single-source data, and that leveraging histology with foundation models can enhance endpoint prediction​. HANCOCK aims to facilitate precision oncology studies by providing a large public resource for developing and benchmarking multimodal machine learning methods in head and neck cancer.

Introduction

Head and neck cancer (HNC) is a prevalent malignancy with poor outcomes – it is the 7th most common cancer globally and carries a 5-year survival of only ~25–60% despite modern treatments​. Improving patient prognosis may require personalized, multimodal therapy decisions, using information from pathology, clinical, and other data sources​. However, progress in multimodal prediction has been limited by the lack of large public datasets that integrate these diverse data types​. To our knowledge, existing HNC datasets are either small or incomplete; for example, a radiomics study included 288 oropharyngeal cases​, and a proteomics-focused set with imaging had only 122 cases​. The Cancer Genome Atlas (TCGA) provides multi-omics for >500 HNC cases, but lacks crucial data like pathology reports, blood tests, or comprehensive imaging for each patient​. These limitations hinder robust multimodal research​.

HANCOCK was created to address this gap​. It aggregates 763 patients’ data from a single academic center, capturing a real-world, uniformly treated cohort. The dataset uniquely combines whole slide histopathology images, tissue microarray images, detailed clinical parameters, pathology reports, and lab values in one resource​​. By curating and harmonizing these modalities, HANCOCK enables researchers to explore complex data interdependencies and develop multimodal predictive models. The patient population reflects typical HNC demographics – 80% male, median age 61, with 72% being former or current smokers​ – aligning with expected epidemiology​ and supporting generalizability. In summary, HANCOCK is an unprecedented multimodal HNC dataset that can fuel research in machine learning, prognostic biomarker discovery, and integrative oncology, ultimately advancing personalized head and neck cancer care.

Methods

The following sections describe how the HANCOCK data were collected, processed, and prepared for public sharing.

Subject Inclusion and Exclusion Criteria

Patients included in HANCOCK were those diagnosed with head and neck cancer between 2005 and 2019 at University Hospital Erlangen (Germany) who underwent a curative-intent initial treatment (surgery and/or definitive therapy)​. This encompasses cancers of the oral cavity, oropharynx, hypopharynx, and larynx​. Patients treated palliatively or with recurrent/metastatic disease at presentation were excluded to focus on first-course, curative treatments. The cohort consists of 763 patients (approximately 80% male, 20% female) with a median age of 61 years​. Notably, ~72% have a history of tobacco use​, which is consistent with real-world HNC risk factors. The distribution of tumor subsites and stages reflects typical HNC presentation, and thus the dataset is broadly representative of the general HNC patient population​. Being a single-center dataset, there is limited geographic diversity; however, the homogeneous data acquisition and treatment context reduce variability in data quality. No significant selection biases were introduced aside from the exclusion of non-curative cases – all major HNC subsite cases over the inclusion period were captured, providing a comprehensive real-world sample. Ethical approval was obtained for this retrospective data collection and sharing (Ethics Committee vote #23-22-Br), and all data were fully de-identified prior to release.

Data Acquisition

Histopathology: Tissue specimens from the primary tumors (and involved lymph nodes, if present) were obtained from the pathology archives. All samples were formalin-fixed and paraffin-embedded (FFPE) and stained with hematoxylin and eosin (H&E) following routine protocols​. Digital whole-slide imaging was performed on these histology slides. A total of 709 H&E slides of primary tumor tissue (701 patients had one slide, 8 patients had two slides) were scanned at high resolution using a 3DHISTECH P1000 scanner at an effective 82.44× magnification (0.1213 µm/pixel). Additionally, 396 H&E slides of lymph node metastases were scanned, using two systems: an Aperio Leica GT450 at 40× (0.2634 µm/pixel) and the 3DHISTECH P1000 at ~51× (0.1945 µm/pixel). (Multiple scanners were utilized over the course of the project; all resulting images were cross-verified for quality.) The digital whole slide images (WSIs) are provided in the pyramidal Aperio SVS format, a TIFF-based format compatible with standard viewers.

In addition to full slides, tissue microarrays (TMAs) were constructed from each patient’s tumor block to sample important regions. For each case, two cylindrical core biopsies (diameter 1.5 mm) were taken – one from the tumor center and one from the invasive tumor front. These cores were assembled into TMA blocks and stained on separate slides with a panel of eight stains: H&E plus immunohistochemical (IHC) markers targeting various immune cells and tumor biomarkers. The IHC markers include CD3, CD8, CD56, CD68, CD163, PD-L1, and MHC-1, which label T cells (CD3, CD8), natural killer cells (CD56), monocytes/macrophages (CD68, CD163), and a tumor immune checkpoint ligand (PD-L1), as well as MHC class I expression. Each core appears on up to 8 stained TMA slides (one per stain), yielding up to 16 TMA images per patient (two cores × eight stains). In the dataset, TMA images are provided for both the tumor-center and tumor-front cores; these too are digitized high-resolution images (consistent microscope settings, ~40×). The combination of WSIs and TMAs yields a rich imaging dataset: 701 patients have at least one primary tumor WSI (62 patients lack WSIs due to unavailable tissue), and all patients have TMA core images unless the tumor block was exhausted. This imaging data offers both broad tissue context from WSIs and targeted cellular detail from TMAs. Manual tumor region annotations are also included for the primary tumor WSIs (see Data Analysis below).

Clinical and Pathology Data: A wide array of non-imaging data was extracted from hospital information systems and pathology reports for each patient. Key demographic variables (age, sex, etc.) and tumor pathology details were collected, including primary tumor site, histologic subtype, grade, TNM stage, resection margin status, depth of invasion, perineural and lymphovascular invasion, and nodal metastasis status. These pathology parameters were recorded in a structured format for each case​​. Standard clinical coding systems were used where applicable: e.g., diagnoses are coded with ICD-10 codes and procedures with OPS codes (the German procedure classification system)​. The dataset includes these codes for each patient’s conditions and treatments. Comprehensive laboratory blood test results at diagnosis or pre-treatment were also compiled, covering complete blood counts, coagulation measures, electrolytes, kidney function, C-reactive protein, and other relevant analytes. Reference ranges for each lab parameter are provided alongside the values to indicate whether a result was normal or abnormal. Most patients have a full panel of these lab results, though some values are missing if a test was not clinically indicated; the dataset notes availability per patient. All structured data have been cleaned and validated – for example, harmonizing category values and checking consistency (e.g. TNM stages align with recorded tumor sites).

Textual Data (Surgical Reports and Histories): Unstructured clinical text was also included to add rich context on treatment details. Surgery reports (operative notes) from the primary tumor resection and associated medical history summaries were retrieved from the hospital’s electronic records. For each patient, the operative report from their first definitive surgery and the corresponding

This statistic shows the death rate of cancer in oral cavity and pharynx in the United States from 1999 to 2023. The maximum death rate in the given period was *** per every 100,000 age-adjusted population.

This statistic shows the death rate of larynx cancer in the United States from 1999 to 2021. The maximum rate of larynx cancer death was *** per 100,000 inhabitants in 1999 and 2000. The minimum rate stood at *** from 2017 to 2021.

Press Coverage from Racial Survival Disparity in Head and Neck Cancer Results from Low Prevalence of Human Papillomavirus Infection in Black Oropharyngeal Cancer Patients

BASE YEAR	2024
HISTORICAL DATA	2019 - 2023
REGIONS COVERED	North America, Europe, APAC, South America, MEA
REPORT COVERAGE	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
MARKET SIZE 2024	8.93(USD Billion)
MARKET SIZE 2025	9.38(USD Billion)
MARKET SIZE 2035	15.2(USD Billion)
SEGMENTS COVERED	Drug Type, Indication, Administration Route, End User, Regional
COUNTRIES COVERED	US, Canada, Germany, UK, France, Russia, Italy, Spain, Rest of Europe, China, India, Japan, South Korea, Malaysia, Thailand, Indonesia, Rest of APAC, Brazil, Mexico, Argentina, Rest of South America, GCC, South Africa, Rest of MEA
KEY MARKET DYNAMICS	increasing prevalence of cancer, rising demand for targeted therapies, advancements in immunotherapy, growing geriatric population, expanding pipeline of drug candidates
MARKET FORECAST UNITS	USD Billion
KEY COMPANIES PROFILED	Regeneron Pharmaceuticals, AstraZeneca, Incyte Corporation, Merck & Co, Exelixis, Seattle Genetics, GlaxoSmithKline, Roche, Sanofi, BristolMyers Squibb, Amgen, Pfizer, Eli Lilly, Novartis, Bayer
MARKET FORECAST PERIOD	2025 - 2035
KEY MARKET OPPORTUNITIES	Innovative immunotherapy advancements, Increased targeted therapy demand, Expanding biomarker development, Growing personalized medicine approaches, Rising incidence rates globally
COMPOUND ANNUAL GROWTH RATE (CAGR)	5.0% (2025 - 2035)

The global market for Squamous Cell Carcinoma of the Head and Neck (SCCHN) treatment is poised for significant expansion, driven by an increasing incidence of head and neck cancers and advancements in therapeutic modalities. With an estimated market size of approximately $7,500 million in 2025 and a projected Compound Annual Growth Rate (CAGR) of 8.5% from 2025 to 2033, the market is expected to reach a substantial valuation by the end of the forecast period. Key growth drivers include rising awareness about early detection and diagnosis, the growing prevalence of risk factors such as HPV infections and tobacco/alcohol consumption, and the continuous development of innovative treatment options, including targeted therapies, immunotherapies, and novel chemotherapy regimens. Furthermore, an aging global population, which is more susceptible to various cancers, also contributes to the market's upward trajectory. The demand for advanced treatment solutions in hospitals, specialty clinics, and ambulatory surgical centers is expected to surge as healthcare providers adopt more sophisticated approaches to combat SCCHN. The competitive landscape is characterized by the presence of major pharmaceutical and biotechnology companies actively engaged in research and development to introduce more effective and personalized treatment strategies. The market segmentation across various cancer sites, including Salivary Gland, Oral & Oropharyngeal, Nasal Cavity & Paranasal Sinus, Nasopharyngeal, and Laryngeal & Hypo Pharyngeal, indicates a diversified demand for specialized treatments. North America currently leads the market, owing to high healthcare expenditure, advanced medical infrastructure, and a strong focus on cancer research. However, the Asia Pacific region is anticipated to witness the fastest growth, fueled by increasing healthcare investments, a growing patient pool, and improving access to advanced SCCHN treatments. Restraints such as the high cost of novel therapies and challenges in early diagnosis in certain demographics are present, but ongoing research and supportive government initiatives are expected to mitigate these factors, ensuring robust market growth in the coming years.

The size of the Throat Cancer Treatment Industry market was valued at USD 5.73 Million in 2023 and is projected to reach USD 12.37 Million by 2032, with an expected CAGR of 11.62% during the forecast period. Recent developments include: October 2022: Philips has received clearance from the FDA for its artificial intelligence-powered MRI platform geared toward head and neck cancers., October 2022: Royal Philips has unveiled two significant breakthroughs in MR-only processes to boost head and neck cancer radiation imaging and simulation.. Key drivers for this market are: Rising in Incidences of Target Diseases, Growing Global Geriatric Population; Technological Advancments and Increasing Number of Diagnostic Procedures for Head and Neck Cancer. Potential restraints include: High Cost of the Devices and Unfavourable Reimbursement Scenarios, Dearth of Trained Professionals. Notable trends are: Diagnostic Imaging Equipment is Expected to Hold a Significant Share in the Head and Neck Cancer Diagnostics Market.

This release summarises the diagnoses in 2019 registered by NDRS covering all registerable neoplasms (all cancers, all in situ tumours, some benign tumours and all tumours that have uncertain or unknown behaviours)

This study describes a subset of the HNSCC collection on TCIA.

PURPOSE:

Cross sectional imaging is essential for the patient-specific planning and delivery of radiotherapy, a primary determinant of head and neck cancer outcomes. Publicly shared RT data is scarce due to high complexity of RT structure data and the need for registration in time, space, and across planning sets. We here introduce an open access imaging database for patients treated with radiotherapy for head and neck squamous cell carcinoma (HNSCC).

MATERIALS AND METHODS:

2840 consecutive patients with HNSCC treated with curative-intent RT at MD Anderson Cancer Center from 2003 to 2013 were screened. Patients with whole-body PET-CT or abdominal CT scans both before and after RT were included (n=215). Clinical data were retrieved from the MD Anderson Cancer Center custom electronic medical record system, ClinicStation. Using cross sectional imaging, we calculated total body skeletal muscle and adipose content before and after treatment. All files were de-identified and transferred to The Cancer Imaging Archive servers using the RSNA Clinical Trial Processor program. Files were screened for errors or residual PHI using TagSniffer and Posda Tools software, reviewed by TCIA curators, then confirmed at the parent institution.

RESULTS:

The HNSCC collection is a dataset consisting of 433,384 DICOM files from 3,225 series and 765 studies collected from 215 patients, which includes de-identified diagnostic imaging, radiation treatment planning, and follow up imaging. All imaging data are subject- and date-matched to clinical data from each patient, including demographics, risk factors, grade, stage, recurrence, and survival.

CONCLUSION:

Recent advances in data archiving, patient de-identification, and image registration have allowed for the creation of a high quality RT-enriched imaging database within TCIA. Open access to these data allows for interinstitutional comparisons of complete RT details in non-randomized patient populations, allowing for a more granular understanding of three dimensional factors that influence treatment effectiveness and toxicity sparing. A related dataset describing the other component of the HNSCC collection is here: Radiomics outcome prediction in Oropharyngeal cancer DOI: 10.7937/TCIA.2020.2vx6-fy46

The global throat cancer treatment market is booming, projected to reach [Insert projected 2033 market size based on your calculations] by 2033, driven by advanced diagnostics, innovative therapies, and rising incidence rates. Discover key market trends, leading companies, and regional growth opportunities in this comprehensive market analysis. Recent developments include: October 2022: Philips has received clearance from the FDA for its artificial intelligence-powered MRI platform geared toward head and neck cancers., October 2022: Royal Philips has unveiled two significant breakthroughs in MR-only processes to boost head and neck cancer radiation imaging and simulation.. Key drivers for this market are: Rising in Incidences of Target Diseases, Growing Global Geriatric Population; Technological Advancments and Increasing Number of Diagnostic Procedures for Head and Neck Cancer. Potential restraints include: Rising in Incidences of Target Diseases, Growing Global Geriatric Population; Technological Advancments and Increasing Number of Diagnostic Procedures for Head and Neck Cancer. Notable trends are: Diagnostic Imaging Equipment is Expected to Hold a Significant Share in the Head and Neck Cancer Diagnostics Market.

Patient numbers and median diagnostic ages for laryngeal and lung cancer in Finland and Sweden, 1967–2019.

This publication reports on newly diagnosed cancers registered in England in addition to cancer deaths registered in England during 2020. It includes this summary report showing key findings, spreadsheet tables with more detailed estimates, and a methodology document.

Abbreviations: N = number; SE = standard error.a.P-values were calculated using chi-squared tests (for categorical variables) or T-tests (for continuous variables).

In Italy, the overall number of new diagnoses of laryngeal cancer in 2020 was higher for men than women. The highest number of new diagnoses was observed among men between 70 and 74 years, with *** new cases. This statistic shows the number of people with a new diagnosis of laryngeal cancer in Italy in 2020, by age group and gender.

Snapshot img

Head And Neck Cancer Diagnostics Market Size 2024-2028

The head and neck cancer diagnostics market size is forecast to increase by USD 6.3 billion at a CAGR of 13.64% between 2023 and 2028.

The market is experiencing significant growth due to the rising incidences of head and neck cancers. This trend is driven by the increasing awareness and early detection of these cancers, leading to a higher demand for accurate and efficient diagnostic tools. Additionally, the use of immunotherapy in head and neck cancer treatment is on the rise, necessitating advanced diagnostic methods to identify the presence of these cancers and determine the most effective treatment options. However, frequent product recalls due to safety concerns and regulatory issues pose a challenge to market growth. It is essential for market players to address these challenges by ensuring stringent quality control measures and adhering to regulatory guidelines to maintain consumer trust and confidence.

What will be the Size of the Head And Neck Cancer Diagnostics Market during the Forecast Period?

Request Free SampleThe market encompasses a range of diagnostic procedures and devices used to identify various types of cancer In the head and neck region, including oropharyngeal and throat cancer. Key diagnostic tools include physical exams, biopsies, and imaging modalities such as endoscopy, MRI, CT, PET/CT, chest imaging, and diagnostic devices. Radiologists and pathologists play crucial roles in interpreting these diagnostic results. Novel technologies, such as molecular and genetic testing, are also gaining traction In the market. The market is experiencing significant growth due to increasing cancer incidences worldwide, a growing focus on early detection, and rising healthcare expenditure. Personal healthcare spending and hospital spending on cancer treatment are major drivers of market growth.Diagnostic imaging and prescription drugs are significant components of the market, while dental care is also becoming increasingly relevant due to the link between oral health and head and neck cancers.

How is this Head And Neck Cancer Diagnostics Industry segmented and which is the largest segment?

The head and neck cancer diagnostics industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD million' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments. Diagnostic MethodsBiopsy and blood testsImagingEndoscopyDental diagnosticsEnd-userHospitalsSpecialty clinicsAmbulatory surgical centersOthersGeographyNorth AmericaUSEuropeGermanyFranceAsiaChinaJapanRest of World (ROW)

By Diagnostic Methods Insights

The biopsy and blood tests segment is estimated to witness significant growth during the forecast period. The global head and neck cancer diagnostic market is primarily driven by the prevalence of oropharyngeal cancer and thyroid nodule assessment. Biopsy and blood tests are the largest diagnostic segments due to their significance in confirming cancer diagnoses. A biopsy involves the removal of tissue or cells for laboratory analysis, with incisional biopsies being commonly used for oral cancer diagnosis. Diagnostic imaging techniques, including endoscopy, MRI, CT, PET/CT, and chest imaging, complement biopsies in identifying cancerous growths. Diagnostic devices, genomic testing, tumor sequencing, molecular profiling, and genetic mutation analysis are emerging technologies in head and neck cancer diagnostics. Reimbursement issues and economic strategies pose challenges to market growth.Early detection and advancements in targeted therapy and immunotherapy are significant trends. Key players In the market include Viome Life Science, CancerDetect, GE Healthcare, and others. Skilled physicians, software technologies, and telemedicine are transforming diagnostic practices. Healthcare expenditure, prescription drugs, dental care, sedentary lifestyle, and chronic diseases contribute to market demand.

Get a glance at the market report of various segments Request Free Sample

The Biopsy and blood tests segment was valued at USD 1.64 billion in 2018 and showed a gradual increase during the forecast period.

Regional Analysis

North America is estimated to contribute 40% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

For more insights on the market size of various regions, Request Free Sample

The market in North America is expected to dominate the global landscape due to the region's high incidence of head and neck cancers, particularly In the US. Notable market participants, such as GE Healthcare and Varian Medical Systems, are headquartered In the US, ensuring the availability of advanced diagnostic equipment. Oropharyngeal cancer, including squamous ce

The RADCURE dataset was collected clinically for radiation therapy treatment planning and retrospectively reconstructed for quantitative imaging research.

Inclusion: The dataset used for this study consists of 3,346 head and neck cancer CT image volumes collected from 2005-2017 treated with definitive RT at the University Health Network (UHN) in Toronto, Canada

Acquisition and Validation Methods: RADCURE contains computed tomography (CT) images with corresponding normal and non-normal tissue contours. CT scans were collected using systems from three different manufacturers. Standard clinical imaging protocols were followed, and contours were generated and reviewed at weekly quality assurance rounds. RADCURE imaging and structure set data was extracted from our institution’s radiation treatment planning and oncology systems using an in-house data mining and processing system. Furthermore, images are linked to clinical data for each patient and include demographic, clinical and treatment information based on the 7th edition TNM staging system. The median patient age is 63, with the final dataset including 80% males. Oropharyngeal cancer makes up 50% of the population with larynx, nasopharynx, and hypopharynx cancer, comprising 25, 12, and 5% respectively. Median follow-up was 5 years with 60% of the patients alive at last follow-up.

Data Format and Usage Notes: During extraction of images and contours from our institution’s radiation treatment planning and oncology systems, the data was converted to DICOM and RTSTRUCT formats, respectively. To improve the usability of the RTSTRUCT files, individual contour names were standardized for primary tumor volumes and 19 organs-at-risk. Demographic, clinical, and treatment information is provided as a comma-separated values (csv) file. This dataset is a superset of the Radiomic Biomarkers in Oropharyngeal Carcinoma (OPC-Radiomics) dataset and fully encapsulates all previous data; this dataset replaces the OPC-Radiomics dataset. The RTSTRUCTs from OPC-Radiomics have been standardized to adhere to the TG263 nomenclature. Age of 90 years or greater is considered PHI and set to 90 years to minimize impact to privacy. Both radiological and clinical metadata were offset by an undisclosed number of days for anonymization and should be noted for downstream analysis. The TG263-standardized RTSTRUCTs include only the GTVp (primary gross tumor volume) contours. Patients without corresponding GTVp contours will not have RTSTRUCTs.

Potential Applications: The availability of imaging, clinical, demographic and treatment data in RADCURE makes it a viable option for a variety of quantitative image analysis research initiatives. This includes the application of machine learning or artificial intelligence methods to expedite routine clinical practices, discover new non-invasive biomarkers, or develop prognostic models.